6838 台新藥歷年利潤比率
| 年度/季別 | 毛利率 | 營業利益率 | 稅前淨利率 | 稅後淨利率 |
|---|
| 2025Q2 | 78.90% | -1085.37% | 1348.64% | 1349.92% |
| 2025Q1 | -112.12% | -5877.61% | -6887.88% | -6867.17% |
| 2024Q4 | 45.06% | -612.43% | -626.28% | -654.33% |
| 2024Q3 | 14.72% | -1197.88% | -1048.83% | -1064.78% |
| 2024Q2 | 72.65% | -1895.66% | -1818.07% | -1816.89% |
| 2024Q1 | 87.50% | 10.47% | -0.27% | -15.19% |
| 2023Q4 | - | - | - | - |
| 2023Q3 | 100.00% | -14279.23% | -21775.74% | -25109.95% |
| 2023Q2 | 87.50% | -456.99% | -433.19% | -442.60% |
| 2022Q4 | 27.68% | -19160.16% | -20783.15% | -20757.92% |
| 2022Q2 | 18.45% | -57765.18% | -60454.17% | -60401.49% |
| 2021Q4 | 100.00% | -76142.38% | -73842.71% | -74710.51% |
| 2021Q2 | 99.05% | -581.75% | -671.00% | -670.42% |